What is BioAge?
BioAge is a biotechnology company focused on harnessing the biology of human aging to develop innovative therapies for metabolic diseases. By utilizing a proprietary platform that integrates 65 million molecular measurements across 45 years of human aging data, the company identifies unique biological insights. Its lead program, azelaprag, is an oral APJ agonist currently entering Phase 2 trials. This candidate is being evaluated in combination with incretin drugs to potentially amplify weight loss and improve body composition in older adults, addressing critical unmet needs in the metabolic therapeutic landscape.
How much funding has BioAge raised?
BioAge has raised a total of $293.9M across 4 funding rounds:
Series A
$10.9M
Series B
$23M
Series C
$90M
Series D
$170M
Series A (2017): $10.9M with participation from Felicis Ventures, AME Cloud Ventures, Pear, Caffeinated Capital, and Andreessen Horowitz LLC
Series B (2019): $23M led by AME Cloud Ventures, Redpoint Ventures, Andreessen Horowitz, Caffeinated Capital, PEAR Ventures, Khosla Ventures, and Felicis Ventures
Series C (2020): $90M supported by AME Cloud Ventures, Phi-X Capital, Kaiser Foundation Hospitals, Redpoint Ventures, Andreessen Horowitz, Felicis Ventures, Caffeinated Capital, PEAR Ventures, AARP Foundation, and Elad Gil
Series D (2024): $170M featuring Longitude Capital, RA Capital Management, RTW Investments, and Cormorant Asset Management
Key Investors in BioAge
Longitude Capital
Longitude Capital is a healthcare-focused venture capital firm that invests in biotechnology, medical technology, and health solutions, providing active partnership to help innovators scale.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies.
RTW Investments
RTW is a life sciences investment and innovation firm that focuses on biotech and medtech innovation throughout the entire lifecycle, from company creation to public markets.
What's next for BioAge?
With the recent capital injection, BioAge is well-positioned to accelerate its clinical development programs, particularly the Phase 2 trials for azelaprag. The strategic focus will likely remain on validating the efficacy of its lead candidate in combination with existing obesity therapies while continuing to mine its vast molecular database for new therapeutic targets. As the company matures, the emphasis will shift toward scaling its clinical operations and potentially expanding its pipeline to address broader age-related metabolic pathways, solidifying its market position as a leader in longevity-focused drug discovery.
See full BioAge company page
